Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals (CSE:AGN) reports positive results of its Phase 2 Ifenprodil study

John Ballem  September 1, 2022

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

GlobeNewswire September 1, 2022

Algernon Pharmaceuticals (CSE:AGN) shareholder AlphaNorth Asset Management increases ownership position

Brieanna McCutcheon  August 23, 2022

Algernon Pharmaceuticals Inc. (CSE:AGN) closes private placement

Azuka Onwuka August 23, 2022

Algernon Pharmaceuticals' Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

GlobeNewswire August 23, 2022

Algernon Pharmaceuticals Announces Closing of Private Placement

GlobeNewswire August 23, 2022

Algernon Pharmaceuticals (CSE:AGN) announces $1.4M private placement

John Ballem  August 18, 2022

Algernon Pharmaceuticals Announces Private Placement

GlobeNewswire August 18, 2022

Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

GlobeNewswire August 3, 2022

Algernon Pharmaceuticals (CSE:AGN) reports “additional positive data” from Phase 2 Study of Ifenprodil

Dave Jackson July 28, 2022

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

GlobeNewswire July 28, 2022

Crossing the finish line: Algernon (CSE:AGN) reaches endpoint in Phase 2a study of Ifenprodil

Dave Jackson July 22, 2022

Algernon Pharmaceuticals (CSE:AGN) achieves co-primary endpoint in its Phase 2 study of Ifenprodil

John Ballem  July 18, 2022

IIROC Trade Resumption - AGN

Canada NewsWire July 18, 2022

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

GlobeNewswire July 18, 2022

IIROC Trading Halt - AGN

Canada NewsWire July 15, 2022

Algernon Pharmaceuticals (CSE:AGN) updates its planned Phase 1 Repirinast Chronic Kidney Disease study

John Ballem  July 11, 2022

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

GlobeNewswire July 11, 2022

Algernon Pharmaceuticals (CSE:AGN) updates Phase 1 DMT human stroke study

John Ballem  July 7, 2022

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

GlobeNewswire July 7, 2022